Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors.
Zhang W, Haines BB, Efferson C, Zhu J, Ware C, Kunii K, Tammam J, Angagaw M, Hinton MC, Keilhack H, Paweletz CP, Zhang T, Winter C, Sathyanarayanan S, Cheng J, Zawel L, Fawell S, Gilliland G, Majumder PK. Zhang W, et al. Among authors: haines bb. Transl Oncol. 2012 Dec;5(6):422-9. doi: 10.1593/tlo.12241. Epub 2012 Dec 1. Transl Oncol. 2012. PMID: 23323157 Free PMC article.
An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies.
O'Neil J, Benita Y, Feldman I, Chenard M, Roberts B, Liu Y, Li J, Kral A, Lejnine S, Loboda A, Arthur W, Cristescu R, Haines BB, Winter C, Zhang T, Bloecher A, Shumway SD. O'Neil J, et al. Among authors: haines bb. Mol Cancer Ther. 2016 Jun;15(6):1155-62. doi: 10.1158/1535-7163.MCT-15-0843. Epub 2016 Mar 16. Mol Cancer Ther. 2016. PMID: 26983881
Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
Witter DJ, Harrington P, Wilson KJ, Chenard M, Fleming JC, Haines B, Kral AM, Secrist JP, Miller TA. Witter DJ, et al. Bioorg Med Chem Lett. 2008 Jan 15;18(2):726-31. doi: 10.1016/j.bmcl.2007.11.047. Epub 2007 Nov 19. Bioorg Med Chem Lett. 2008. PMID: 18060775
A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, Arthur W, Roberts B, Zhang T, Chenard M, Haines B, Andersen J, Nagashima K, Paweletz C, Lynch B, Feldman I, Dai H, Huang P, Watters J. Loboda A, et al. BMC Med Genomics. 2010 Jun 30;3:26. doi: 10.1186/1755-8794-3-26. BMC Med Genomics. 2010. PMID: 20591134 Free PMC article.
Divergent kinetics differentiate the mechanism of action of two HDAC inhibitors.
Kral AM, Ozerova N, Close J, Jung J, Chenard M, Fleming J, Haines BB, Harrington P, Maclean J, Miller TA, Secrist P, Wang H, Heidebrecht RW Jr. Kral AM, et al. Among authors: haines bb. Biochemistry. 2014 Feb 4;53(4):725-34. doi: 10.1021/bi400936h. Epub 2014 Jan 22. Biochemistry. 2014. PMID: 24450491
Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (SHI-1:2).
Heidebrecht RW Jr, Chenard M, Close J, Dahlberg WK, Fleming J, Grimm JB, Hamill JE, Harsch A, Haines BB, Hughes B, Kral AM, Middleton RE, Mushti C, Ozerova N, Szewczak AA, Wang H, Wilson K, Witter DJ, Secrist JP, Miller TA. Heidebrecht RW Jr, et al. Among authors: haines bb. Bioorg Med Chem Lett. 2009 Apr 1;19(7):2053-8. doi: 10.1016/j.bmcl.2009.02.009. Epub 2009 Feb 8. Bioorg Med Chem Lett. 2009. PMID: 19268585
Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor.
Methot JL, Hoffman DM, Witter DJ, Stanton MG, Harrington P, Hamblett C, Siliphaivanh P, Wilson K, Hubbs J, Heidebrecht R, Kral AM, Ozerova N, Fleming JC, Wang H, Szewczak AA, Middleton RE, Hughes B, Cruz JC, Haines BB, Chenard M, Kenific CM, Harsch A, Secrist JP, Miller TA. Methot JL, et al. Among authors: haines bb. ACS Med Chem Lett. 2014 Jan 2;5(4):340-5. doi: 10.1021/ml4004233. eCollection 2014 Apr 10. ACS Med Chem Lett. 2014. PMID: 24900838 Free PMC article.
SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
Methot JL, Hamblett CL, Mampreian DM, Jung J, Harsch A, Szewczak AA, Dahlberg WK, Middleton RE, Hughes B, Fleming JC, Wang H, Kral AM, Ozerova N, Cruz JC, Haines B, Chenard M, Kenific CM, Secrist JP, Miller TA. Methot JL, et al. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. doi: 10.1016/j.bmcl.2008.10.052. Epub 2008 Oct 14. Bioorg Med Chem Lett. 2008. PMID: 18951790
High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide.
Guertin AD, O'Neil J, Stoeck A, Reddy JA, Cristescu R, Haines BB, Hinton MC, Dorton R, Bloomfield A, Nelson M, Vetzel M, Lejnine S, Nebozhyn M, Zhang T, Loboda A, Picard KL, Schmidt EV, Dussault I, Leamon CP. Guertin AD, et al. Among authors: haines bb. Mol Cancer Ther. 2016 Aug;15(8):1998-2008. doi: 10.1158/1535-7163.MCT-15-0950. Epub 2016 Jun 2. Mol Cancer Ther. 2016. PMID: 27256377
28 results